Abstracts Archive - Page 165 of 2607 - ACR Meeting Abstracts

Abstract Number: 0911 • ACR Convergence 2025
A Novel FcRn × Albumin Bispecific Antibody Demonstrates Extended Half-life and Deep IgG Reduction in Preclinical Mouse Models
Hang Su¹, Lulu Li¹, Zenglin Pei¹, Barry Duplantis², Yuhao Wang², Yi Li¹ and Quan Yu¹, ¹Ailux, Shanghai, China (People's Republic), ²Ailux, Boston, MA
Background/Purpose: Autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s syndrome are characterized by elevated levels of pathogenic autoantibodies that drive inflammation. The…
Abstract Number: 0910 • ACR Convergence 2025
Development of Four Distinct Human IgG4-Producing Mouse Models Recapitulating IgG4-Related Disease
MIN GANG KIM¹, JINA YEO², HEA RIM KANG³, JAE HYUN MOON³, Seon Uk Kim⁴, SeoYoon Ban⁵, MI HYEON KIM⁶ and Eun Young Lee⁷, ¹Seoul National University College of Medicine, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea, ³Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, ⁴Seoul National University, Jongno-gu, Seoul, Republic of Korea, ⁵Department of Cancer biology, Graduate School of College of Medicine, Seoul National University, Korea, Seoul, Republic of Korea, ⁶Hallym university dongtan sacred heart hospital, Seocho-gu, Seoul, Republic of Korea, ⁷Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: IgG4-related disease (IgG4RD) is an immune-mediated fibroinflammatory condition characterized by multi-organ involvement, elevated serum IgG4, and IgG4-positive plasma cell infiltrates that form tumor-like lesions…
Abstract Number: 0907 • ACR Convergence 2025
Cross-Species Cellular Mapping and Humanization of Fcγ Receptors to Advance Antibody Modeling
Karel Van Damme¹, Dorine Sichien², Katrien Van der Borght³, Sofie Van Gassen³, Elisabeth De Leeuw³, Victor Bosteels⁴, Joseph Jorssen⁵, Seppe De Winter⁶, Alan Korman⁷, Fabio Benigni⁸, Davide Corti⁸, Ariane Morel⁹, Eric Vivier⁹, Hamida Hammad³, Dirk Elewaut¹⁰, Fabiane Sonego¹¹, Kader Thiam¹¹, Sofie Voet², bianca Balbino¹² and Bart Lambrecht³, ¹Ghent University, Ghent, ²argenx, Ghent, Belgium, ³Ghent University, Ghent, Belgium, ⁴The Francis Crick Institute, London, United Kingdom, ⁵Liège Université, Liege, Belgium, ⁶KU Leuven, Leuven, Belgium, ⁷Vir Biotechnology, San Francisco, ⁸Vir Biotechnology, Bellinzona, Switzerland, ⁹Innate Pharma, Marseille, France, ¹⁰VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ¹¹genOway, Lyon, France, ¹²argenx, Gent, Belgium
Background/Purpose: Fc receptors mediate the effector functions of antibodies by linking adaptive and innate immunity. Immunoglobulin G (IgG), the most abundant antibody in circulation and…
Abstract Number: 0717 • ACR Convergence 2025
Circulating Bacterial sRNAs are Altered in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Christopher Xavier¹, Kevin Byram², Carol Langford³ and Michelle Ormseth⁴, ¹Meharry Medical College, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Cleveland Clinic, Moreland Hills, OH, ⁴Vanderbilt University Medical Center, Nashville
Background/Purpose: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (AAV) is an autoimmune disease causing small vessel inflammation. Underlying mechanisms of disease are unclear, but the human microbiota may…
Abstract Number: 0916 • ACR Convergence 2025
UVB-Irradiated Keratinocyte Extracellular Vesicles Trigger Innate Immune Activation via Type I Interferons and STING Pathway
Ahmed Eldaboush¹, Darae Kang² and Victoria Werth³, ¹Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Potomac, MD, ³University of Pennsylvania, Wynnewood, PA
Background/Purpose: Extracellular vesicles (EVs) are cell-derived nanoparticles that mediate cell-cell communication. EVs are implicated in photosensitive autoimmune diseases like dermatomyositis (DM) and systemic lupus (SLE),…
Abstract Number: 0918 • ACR Convergence 2025
Retention of variant forms of TNFR1 in the Golgi induces stress responses and monocyte activation in systemic Juvenile Idiopathic Arthritis (sJIA)
Anthony Cruz¹, Krisztian Csomos¹, Boglarka Ujhazi¹, Hiroto Nakano², Marissa Krantz³, Sophia Chou⁴, Emily Rosenbaum¹, Tianmin Fu⁵, Dirk Foell⁶, Rae Yeung⁷, Pamela Weiss⁸, Faiza Naz⁹, Ly-Lan Bergeron¹, Michelle Millwood¹⁰, Carol Lake¹¹, Emely Verweyen⁶, Grant Schulert¹², Stefania Dell'orso⁹, Hao Wu¹³, Zuoming Deng¹⁴, davide Randazzo¹⁵ and Michael Ombrello¹⁶, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³University of Rochester, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Rockville, MD, ⁵Ohio State University College of Medicine, Columbus, OH, ⁶University Hospital Muenster, Muenster, Germany, ⁷The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁸Childrens Hospital of Philadelphia, Philadelphia, PA, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ¹⁰National Institutes of Health (NIH), Bethesda, MD, ¹¹NIH, GAITHERSBURG, MD, ¹²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Harvard University, Cambridge, MA, ¹⁴Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁵Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ¹⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is severe and poorly understood inflammatory condition. Tumor necrosis factor receptor 1 (TNFR1) is activated by TNF and is…
Abstract Number: 0639 • ACR Convergence 2025
Kidney Transplantation In Lupus Nephritis. Multicenter Study Of 103 Patients
Vanesa Calvo-Río¹, Lara Sánchez Bilbao¹, Carmen Secada-Gómez¹, Paúl Hernández Velasco², Celia González-García³, Enrique Morales⁴, María Galindo-Izquierdo⁵, Sebastián Sandoval-Moreno⁶, Josefina Cortés-Hernández⁷, César Antonio Egües Dubuc⁸, Niccolo Viveros-Pérez⁹, María Caeiro¹⁰, Adrián Mayo-Juanatey¹¹, Miriam Retuerto Guerrero¹², María Camila Osorio-Sanjuan¹³, Luis Sala¹⁴ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Nephrology, Hospital Universitario ¹² de Octubre, Madrid. Spain, Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Madrid, Spain, ⁴Nephrology, Hospital Universitario ¹² de Octubre, Madrid, Madrid, Spain, ⁵Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ⁶Hospital Universitario Vall D'Hebron, Barcelona, Spain, ⁷Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ⁸Donostia University Hospital, San Sebastián, Pais Vasco, Spain, ⁹Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ¹⁰Centro Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ¹¹Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, ¹²Complejo Asistencial Universitario de León, Leon, Castilla y Leon, Spain, ¹³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹⁴Hospital Universitario de Torrejón, Madrid, Spain
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE) affecting to 40-60% of SLE. End-stage renal disease (ESRD) occurs in up…
Abstract Number: 0909 • ACR Convergence 2025
Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.
Marcus Hines¹, Timothy Borbet² and Sergei Koralov², ¹New York University Grossman School of Medicine, New York, NY, ²NYU Langone Medical Center, New York
Background/Purpose: The microRNA(miR)29 family is encoded by two separate loci, the miR29ab1 and miR29b2c alleles. We have previously shown that the microRNA(miR)29 family regulates the…
Abstract Number: 0660 • ACR Convergence 2025
Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
J. Michelle Kahlenberg¹, Victoria Werth², Joerg Wenzel³, John Schwarz⁴, Jinqi Liu⁴ and Brandon Johnson⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in moderate to severe plaque psoriasis, has demonstrated significant improvements in cutaneous manifestations…
Abstract Number: 0930 • ACR Convergence 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Blocks Pro-Inflammatory Cytokines and Reduces Joint Swelling in a Mouse Model of Rheumatoid Arthritis
Ryan Camire¹, Yi Zhang², Virginia Massa², Jordan Leedberg², Erik Corcoran², Emily Lurier², Chris Carroll², Chris Ho², Dapeng Chen², Bradley Enerson², Revonda Mehovic², Ziyan Zhao², Lincoln Howarth², Susanne Breitkopf², Sarah Martinez², Melissa Ford², Xue Fei², Murugappan Sathappa², Juliet Williams³, Matthew Weiss³, Arsalan Shabbir³, Nello Mainolfi⁴ and Veronica Campbell², ¹Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², MA, ²Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², ³Kymera Therapeutics, Watertown, ⁴Kymera Therapeutics, Watertown, MA
Background/Purpose: IRF5, an undrugged transcription factor, is an autoimmune susceptibility gene that has been linked to RA and other autoimmune diseases including SLE, Sjögren’s, and…
Abstract Number: 0926 • ACR Convergence 2025
Discovery and Characterization of SIM0711: a Potent and Selective IRAK4 PROTAC with Improved Efficacy and Safety
Minyun Zhou¹, Peng Gu², Mengyu Wang³, Yuxi Yan², Li Sun³, Yiling Chen³, Xin Wang³, Feng Tang¹, Shunwei Zhu² and Xiaofeng Zhao⁴, ¹State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing, ²State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), ³State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ⁴State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic)
Background/Purpose: IRAK4 plays a pivotal role in the innate immune response by acting downstream of Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R), with both…
Abstract Number: 0919 • ACR Convergence 2025
Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns
Stefanie Kurth¹, Andre Tiaden¹, Edveena Hanser¹, Simone Häner¹, Stavros Giaglis¹, Florian Geier¹, Dominik Burri¹, Katarzyna Buczak¹, Ute Heider², Stefan Wild², Yves Acklin¹, Christian Egloff¹ and Diego Kyburz³, ¹University of Basel, Basel, Switzerland, ²Miltenyi Biotec, Bergisch-Gladbach, Germany, ³University Hospital Basel, Basel, Switzerland
Background/Purpose: Extracellular vesicles (EVs) are secreted by virtually all cells and are known to carry bioactive cargo including proteins, RNA, DNA and metabolites. Analysis of…
Abstract Number: 0914 • ACR Convergence 2025
Preclinical Expansion of Autoreactive Naive B cells Drives RA onset in ACPA+ individuals
Xiaohao Wu¹, Mengrui Zhang², Orr Sharpe³, V. Michael Holers⁴, Jane Buckner⁵, Gary Firestein⁵, Eddie James⁶, Kevin Deane⁷ and William H. Robinson⁸, ¹Stanford Uniersity, Stanford, ²Stanford University, Stanford, CA, ³Stanford University, Stanford, ⁴University of Colorado Anschutz Medical Campus, Aurora, ⁵Benaroya Research Institute, Seattle, ⁶Benaroya Research Institute, Benaroya Research Institute, ⁷University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁸Stanford University, Palo Alto, CA
Background/Purpose: The cellular and molecular mechanisms underlying the progression from anti-citrullinated protein antibody (ACPA) positivity to clinical rheumatoid arthritis (RA) remain poorly understood. Defining these…
Abstract Number: 2481 • ACR Convergence 2025
Prevalence and Trends of Suicidal Ideation Among Hospitalized Adults with Systemic Lupus Erythematosus (SLE): A National Inpatient Sample Analysis (2016–2020)
Fatima Khdeir and Aysheh Khdeir, ECU Health Medical Center, Greenville, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with psychiatric comorbidities, including depression and suicidal ideation. However, national trends over time have…
Abstract Number: 0663 • ACR Convergence 2025
iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
Parastoo Fazeli¹, Jennifer Medlin², Andrew BitMansour³, Debra Zack⁴, Rebecca Elstrom⁵, Bertha Villa⁵, Lilly Wong⁶, John Goulding⁷, Nicholas Brookhouser⁵, Trever Greene⁵, Cara Bickers⁵, Carol Wong⁵, Beatrice Ferguson⁵, Tom Lee⁵, Jode Goodridge⁵, Marie Hu⁸, Veronika Bachanova⁸, Jeffrey Miller⁹, Bahram Valamehr⁶, Matthew Lunning¹⁰ and Vaneet Sandhu⁵, ¹UMN, ST PAUL, MN, ²University of Nebraska Medical Center, Omaha, NE, ³Fate Therapeutics, Inc., San Carlos, CA, ⁴Fate Therapeutics, Inc., Solana Beach, CA, ⁵Fate Therapeutics, Inc., San Diego, ⁶Fate Therapeutics, Inc., San Diego, CA, ⁷Fate Therapeutics, San Diego, ⁸University of Minnesota, Minneapolis, ⁹University of Minnesota, Minneaspolis, MN, ¹⁰University of Nebraska, Omaha
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy shows promise in autoimmune disease. However, autologous CAR T-cell therapy is limited by prolonged pre- and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].